Relief Therapeutics Holding SA / Key word(s): Agreement/Product Launch Ad hoc announcement pursuant to Art. 53 LR Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA (ACER-001) with Acer Therapeutics GENEVA (AUG. 30, 2023) - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has entered into a new exclusive definitive licensing agreement with Acer Therapeutics Inc. (Acer Therapeutics) for the development and commercialization of OLPRUVA (sodium phenylbutyrate, ACER-001) for the treatment of certain urea cycle disorders (UCDs) and other potential indications. This agreement supersedes the March 2021 collaboration and license agreement between the companies, which has been cancelled as part of this new agreement.
Additional features: File: RLF Ad Hoc Press Release Acer-OLPRUVA New CLA August 30 2023 End of Inside Information |
Language: | English |
Company: | Relief Therapeutics Holding SA |
Avenue de Secheron 15 | |
1202 Geneva | |
Switzerland | |
Phone: | +41 22 545 11 16 |
E-mail: | contact@relieftherapeutics.com |
Internet: | https://relieftherapeutics.com |
ISIN: | CH0100191136 |
Valor: | 10019113 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1714373 |
End of Announcement | EQS News Service |
1714373 30-Aug-2023 CET/CEST